GSK plc
corporate_fare Company Profile
GSK plc (NYSE:GSK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 65 items for GSK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GSK spans 6-K.
Recent high-impact activity:
- FDA Grants Accelerated Approval to GSK's Neladalkib for ALK-Positive Lung Cancer
- GSK Beats Q3 Estimates but Vaccine Slump and £1B Restructuring Charge Drag Shares Down 3.5%
- GSK Q3: Core EPS +1% CER, Guidance Reaffirmed, New £2.4bn Accelerate Growth Restructuring
- GSK Beats on Q3 Core EPS, Reaffirms 2026 Guidance as Specialty Drugs Offset Vaccine Slump
- Ris-Rez Cuts Osteosarcoma Progression Risk 67% in China Phase III
Financial Snapshot
Short Interest & Short Volume
3.18 days to coverFINRA reported short interest of 16,148,828 shares in GSK as of the October 30, 2026 settlement, a 10.8% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 44.5% of GSK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GSK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.